Paul Sekhri, Chairman of the Board, commented:
“After an extensive search, the Board is pleased to nominate Dr. Richard Peters as the new Chairman of the Board of Directors. Dr. Peters is a highly respected and proven industry leader, who brings extensive medical and commercial acumen for difficult-to-treat and rare diseases, from development stage to large global biopharmaceutical companies. I am delighted that Dr. Peters will become my successor following his appointment by the general meeting.”
Richard Peters commented:
“I am honored to have been nominated to become the new Chairman of the Board of Directors of Pharming, as successor to Mr. Paul Sekhri. I look forward to working together with the members of the Board of Directors and the Executive Committee in helping propel Pharming to achieve its long-term strategic objectives, guided by Pharming’s clear vision and mission to become the rare disease company of choice to serve the unserved rare disease patient.”
Dr. Richard Peters (60 years of age, Belgian national, US citizen) has over 30 years of experience in the healthcare industry and academia. He currently serves as Non-Executive Director for Kineta (NASDAQ:KA) and Aprea Therapeutics (NASDAQ:APRE), and is the founder and Executive Chairman of TellBio (private company). He is also a corporate advisor to Aura Biosciences.
Prior to these roles, Dr. Peters served as the Global Head for the Rare Diseases business at Sanofi Genzyme, and CEO of two Nasdaq-listed biotechnology companies: Yumanity Therapeutics and Merrimack Pharmaceuticals. Earlier in his career, Dr. Peters held medical leadership positions at Amgen, Onyx Pharmaceuticals, Genzyme, and Sanofi, and is a founder of X4 Therapeutics (NASDAQ:XFOR) and PIC Therapeutics (private). He has also served on the faculty at the Massachusetts General Hospital, served as editor for the journals SCIENCE and JAMA, and has published over 100 editorial and research articles.
He completed Internal Medicine training at the Massachusetts General Hospital and a Howard Hughes post-doctoral fellowship at Harvard Medical School; both in Boston, MA. Dr. Peters holds an M.D. Degree and a PhD. in Pharmacology from the Medical University of South Carolina, Charleston, South Carolina, and began his medical studies at the Universite Catholique de Louvain in Belgium prior to immigrating to the US.